Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 24953419)


Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization.

Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic LJ, Tacher V, Kamel IR, Geschwind JF.

Transl Oncol. 2014 Aug;7(4):447-55. doi: 10.1016/j.tranon.2014.05.004. Epub 2014 Jun 20.


Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach.

Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J, Chao M, Wang Z, Frangakis C, Sohn JH, Maltenfort MG, Pawlik T, Geschwind JF.

Radiology. 2015 Jul 1:142951. [Epub ahead of print]


Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.

Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.

Radiology. 2013 Aug;268(2):431-9. doi: 10.1148/radiol.13121637. Epub 2013 Apr 24.


Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.

Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z, Savic LJ, Geschwind JF.

Eur Radiol. 2015 Jul;25(7):1993-2003. doi: 10.1007/s00330-015-3595-5. Epub 2015 Jan 31.


Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers.

Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF.

Radiology. 2015 May;275(2):438-47. doi: 10.1148/radiol.14141180. Epub 2014 Dec 19.


Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver - the use of imaging biomarkers as predictors of patient survival.

Chapiro J, Duran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang Z, Geschwind JF.

Eur J Radiol. 2015 Mar;84(3):424-30. doi: 10.1016/j.ejrad.2014.11.034. Epub 2014 Dec 13.


Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.

Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF.

J Vasc Interv Radiol. 2007 Aug;18(8):957-63.


Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.

Vandecaveye V, Michielsen K, De Keyzer F, Laleman W, Komuta M, Op de beeck K, Roskams T, Nevens F, Verslype C, Maleux G.

Radiology. 2014 Mar;270(3):747-57. doi: 10.1148/radiol.13130591. Epub 2013 Dec 12.


Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis.

Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF.

Radiology. 2014 Dec;273(3):746-58. doi: 10.1148/radiol.14140033. Epub 2014 Jul 15.


Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS, Lee CH, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.

J Hepatol. 2013 Jun;58(6):1181-7. doi: 10.1016/j.jhep.2013.01.039. Epub 2013 Feb 8.


Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.

Li Z, Bonekamp S, Halappa VG, Corona-Villalobos CP, Pawlik T, Bhagat N, Reyes D, Lai H, Geschwind JF, Kamel IR.

Radiology. 2012 Jul;264(1):97-109. doi: 10.1148/radiol.12112161. Epub 2012 May 24.


Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data.

Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR.

Radiology. 2011 Sep;260(3):752-61. doi: 10.1148/radiol.11102330. Epub 2011 Jul 19.


Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response.

Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF, Kamel IR.

Radiology. 2012 Jul;264(1):285-94. doi: 10.1148/radiol.12112142. Epub 2012 May 24.


EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.

Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.

Clin Cancer Res. 2014 Mar 15;20(6):1623-31. doi: 10.1158/1078-0432.CCR-13-1716. Epub 2014 Feb 3.


Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization.

Vossen JA, Kamel IR, Buijs M, Liapi E, Georgiades CS, Hong K, Geschwind JF.

J Comput Assist Tomogr. 2008 May-Jun;32(3):347-52. doi: 10.1097/RCT.0b013e318134ecd6.


Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?

Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C.

Radiology. 2012 Oct;265(1):115-23. Epub 2012 Aug 13.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk